TMD & Associates’s Perspective Therapeutics CATX Stock Holding History

TMD & Associates’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$8K	Hold	2,000	–	–	0.01%	45
2019 Q1	$7K	Hold	2,000	–	–	0.01%	43
2018 Q4	$6K	Hold	2,000	–	–	﹤0.01%	40
2018 Q3	$10K	Hold	2,000	–	–	0.01%	39
2018 Q2	$9K	Hold	2,000	–	–	0.01%	25
2018 Q1	$8K	Hold	2,000	–	–	0.01%	17
2017 Q4	$8K	Hold	2,000	–	–	0.01%	18
2017 Q3	$10K	Hold	2,000	–	–	0.01%	20
2017 Q2	$13K	Hold	2,000	–	–	0.01%	19
2017 Q1	$12K	Hold	2,000	–	–	0.01%	22
2016 Q4	$12K	Buy	+2,000	New	+$12.2K	0.01%	27

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HPWM

Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CWM

Cahaba Wealth Management Atlanta, Georgia $1.47B AUM 13.36% 1-Year Est. Return

CAG

Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return

TMD & Associates's CATX Position: Q2 2019 in Review

TMD & Associates held its Perspective Therapeutics (CATX) position steady in Q2 2019 at 2,000 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #45.

TMD & Associates first reported a position in CATX in Q4 2016 and has held it in 11 quarters since. The position peaked at $13K in Q2 2017. 29 funds tracked by Wall St. Rank hold CATX as of Q2 2019.

TMD & Associates held 2,000 shares of Perspective Therapeutics worth $8K as of Q2 2019.
TMD & Associates left its Perspective Therapeutics share count unchanged in Q2 2019.
Perspective Therapeutics made up 0.01% of TMD & Associates's portfolio in Q2 2019, its #45 holding.
TMD & Associates first reported a position in Perspective Therapeutics in Q4 2016 and has held it in 11 quarters since.
TMD & Associates's Perspective Therapeutics position peaked at $13K in Q2 2017.
29 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2019.

Based on TMD & Associates's 13F filing for Q2 2019, filed 9 Aug 2019.